Trial Profile
Expanded Access: Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Mild or Moderate Coronavirus Disease (COVID-19)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications COVID 2019 infections; Pneumonia; Severe acute respiratory syndrome
- Focus Expanded access; Therapeutic Use
- Sponsors Bellerophon Therapeutics
- 13 Jul 2020 Results presented in a Bellerophon Therapeutics media release.
- 10 Jun 2020 Status changed from recruiting to completed.
- 03 Apr 2020 New trial record